Overview

A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
0
Participant gender:
All
Summary
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients who are currently on metformin monotherapy.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
ConjuChem
Treatments:
Metformin
Criteria
Major Inclusion Criteria:

- BMI: 27 to 45 kg/m2

- Stable Type 2 diabetes mellitus for at least 3 months, as defined by the Investigator

- Stable life-style, i.e. diet & physical activity, as determined by the Investigator

- Stable metformin daily dose ≥1000 mg for at least 3 months

- Glycosylated hemoglobin (HbA1c) at screening ≥ 7.1% and ≤ 11%